An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored therapy for safety and stability. Dr. Sambhara presents an 82-year-old monocular ...

An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability. Dr. Sambhara closes with ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies. The lesion characteristics of patients ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination. Topcon Healthcare, Inc, announced it has ...

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...